5,551
Views
25
CrossRef citations to date
0
Altmetric
Review

Chloroquine-containing compounds: a patent review (2010 – 2014)

, , , PhD & , PhD (Professor)

Bibliography

  • Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963;12:121-8
  • Loeb F, Clark W, Coatney GR, et al. Activity of a new antimalarial agent, chloroquine (SN 7618). J Am Med Assoc 1946;130:1069-70
  • Most H, London IM, Kane CA, et al. Chloroquine for treatment of acute attacks of vivax malaria. J Am Med Assoc 1946;131:963-7
  • Goldberg DE, Slater AF, Cerami A, Henderson GB. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci USA 1990;87:2931-5
  • Solomon VR, Haq W, Smilkstein M, et al. 4-aminoquinoline derived antimalarials: synthesis, antiplasmodial activity and heme polymerization inhibition studies. Eur J Med Chem 2010;45:4990-6
  • Kumar S, Guha M, Choubey V, et al. Antimalarial drugs inhibiting hemozoin (β-hematin) formation: a mechanistic update. Life Sci 2007;80:813-28
  • Young MD, Moore DV. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 1961;10:317-20
  • Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001;184:770-6
  • World Health Organization. Guidelines for the treatment of malaria. 2nd edition. 2010. Geneva: World Health Organization, 2010
  • World Health Organization. WHO model list of essential medicines. 18th edition. 2013. Geneva: World Health Organization, 2013
  • Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis 1960;19:243-50
  • Lambert DG. Disease-modifying anti-rheumatic drugs. Anaesth Intensive Care Med 2009;10:35-7
  • Goldman L, Cole DP, Preston RH. Chloroquine diphosphate in treatment of discoid lupus erythematosus. J Am Med Assoc 1953;152:1428-9
  • Lee S-J, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718-29
  • Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009;625:220-33
  • Sasaki K, Tsuno NH, Sunami E, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010;10:370-80
  • The University of Liverpool. Anti-malarial compounds. US7132431; 2006
  • Okombo J, Kiara SM, Abdirahman A, et al. Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in Pfcrt and Pfmdr1 genes. J Antimicrob Chemother 2013;68:786-8
  • Portland State University and State of Oregon. Quinoline derivatives and uses thereof. US2013310348; 2013
  • Peyton DH. Reversed chloroquine molecules as a strategy to overcome resistance in malaria. Curr Top Med Chem 2012;12:400-7
  • Zishiri VK, Joshi MC, Hunter R, et al. Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (Pfcrt). J Med Chem 2011;54:6956-68
  • Gemma S, Campiani G, Butini S, et al. Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials. J Med Chem 2009;52:502-13
  • Campiani G. Novel 4-amino-quinoline derivatives useful as anti-malaria drugs. US2010093726; 2010
  • Advanced Applied Physics Solutions Inc. Carbohydrate-metallocene-antimalarial conjugates. WO2010094130; 2010
  • University of South Florida. Polyacrylate Nanoparticle Drug Delivery. US2010278920; 2010
  • Georgetown University. Antimalarial Quinolines and Methods of Use Thereof. US2011045100; 2011
  • Madrid PB, Liou AP, DeRisi JL, Guy RK. Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum. J Med Chem 2006;49:4535-43
  • Stocks PA, Raynes KJ, Bray PG, et al. Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J Med Chem 2002;45:4975-83
  • Nagoya City University. Compound with antimalarial activity and antimalarial drug containing the same as active ingredient. US7973027; 2011
  • Riscoe MK, Winter RW, Hinrichs DJ. Compounds for treating parasitic disease. US2011251209; 2011
  • Oregon Health & Science University and The US Department of Veterans Affairs. Compounds, compositions and associated methods comprising 3-aryl quinolines. WO2013106847; 2013
  • Portland State University and Designmedix Inc. Modified chloroquines with single ring moiety or fused ring moiety. US2011251210; 2011
  • Designmedix Inc. Modified chloroquines with branched moiety. WO2010065925; 2010
  • University of Wuerzburg and the University of Heidelberg. Hybrid compounds of 4- and 8-aminoquinolines for the prophylactic and therapeutic treatment of malaria and other parasitic diseases. WO2012048894; 2012
  • James LM, Wei TKS. Synthesis and use of fluorophore-tagged antimalarials. US2012100555; 2012
  • Penarete-Vargas DM, Boisson A, Urbach S, et al. A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry. PLoS One 2014;9:1-23
  • Sutherland CJ, Drakeley CJ, Obisike U, et al. The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in gambian children delays, but does not prevent treatment failure. Am J Trop Med Hyg 2003;69:19-25
  • Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008;46:985-91
  • Sanofi-Aventis. Association between ferroquine and an artemisinine derivative for treating malaria. US20120258945; 2012
  • Romanelli F, Smith KM, Hoven AD. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharm Des 2004;10:2643-8
  • Vausselin T, Calland N, Belouzard S, et al. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 2013;58:86-97
  • Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet 2003;3:722-7
  • Bönsch C, Kempf C, Mueller I, et al. Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis 2010;4:1-8
  • Savarino A, Lucia MB, Rastrelli E, et al. Anti-HIV effects of chloroquine. JAIDS J Acquir Immune Defic Syndr 2004;35:223-32
  • Nathoo S, Serghides L, Kain KC. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 2003;362:1039-41
  • He Z, Qin L, Chen L, et al. Synergy of Human Immunodeficiency Virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrob Agents Chemother 2008;52:2653-6
  • Kinch M, Goldblatt M; Functional Genetics Inc. Methods of inhibiting viral infection. US2012142731; 2012
  • Obi Justice. Compositions and methods for treating warts associated with viral infections. US2014011838; 2014
  • Chaozhou Hybribio Ltd. Combined drug for treating verruca diseases. CN104013625; 2014
  • Genoscience Pharma SAS and Panmed Ltd. Treatment of Hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent. US2013202556; 2013
  • Halfon P; Panmed Ltd. Treatment of hepatitis C virus. US2014135259; 2014
  • Roberts PJ, Williams SL, Linch DC. The regulation of neutrophil phospholipase A2 by granulocyte-macrophage colony-stimulating factor and its role in priming superoxide production. Br J Haematol 1996;92:804-14
  • Sakuta H, Yoneda I. Inhibition by SKF525A and quinacrine of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed xenopus oocytes. Eur J Pharmacol 1994;252:117-21
  • Földes-Filep E, Filep JG. Mepacrine inhibits fMLP-induced activation of human neutrophil granulocytes, leukotriene B4 formation, and fMLP binding. J Leukoc Biol 1992;52:545-50
  • Mattsson E, Van Dijk H, Van Kessel K, et al. Intracellular pathways involved in tumor necrosis factor-alpha release by human monocytes on stimulation with lipopolysaccharide or staphylococcal peptidoglycan are partly similar. J Infect Dis 1996;173:212-18
  • Albani Salvatore. Combination therapy method and formulation. US2010021485; 2010
  • Silva JC, Mariz HA, Rocha LF, et al. Hydroxychloroquine decreases TH17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 2013;68:766-71
  • Boissy RE. Melanosome transfer to and translocation in the keratinocyte. Exp Dermatol 2003;12(Suppl 2):5–12
  • Ni-Komatsu L, Tong C, Chen G, et al. Identification of quinolines that inhibit melanogenesis by altering tyrosinase family trafficking. Mol Pharmacol 2008;74:1576-86
  • Hall AM, Orlow SJ. Degradation of tyrosinase induced by phenylthiourea occurs following golgi maturation. Pigment Cell Res 2005;18:122-9
  • New York University. Methods and agents for treating tyrosinase-positive albinism. WO2014186344; 2014
  • Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract 2002;55:209-19
  • Bevan AP, Christensen JR, Tikerpae J, Smith GD. Chloroquine augments the binding of insulin to its receptor. Biochem J 1995;311:787-95
  • Munro R, Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:374-7
  • Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5(Suppl 1):S59-64
  • St. Jude Children’s Research Hospital and The Washington University. Use of chloroquine to treat metabolic syndrome. US8440695; 2013
  • IPCA Laboratories Ltd. Pharmaceutical Combination. US2014128402; 2014
  • Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83
  • Ashutosh S, Sudhir S. Methods and compositions for managing cardiovascular disease associated with chronic kidney disease. US2013210861; 2013
  • Bachmeyer C, Benz R, Barth H, et al. Interaction of Clostridium botulinum C2 toxin with lipid bilayer membranes and Vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo. FASEB J 2001;15:1658-60
  • Liang YF, Peterson JW, Jackson CA, Reitmeyer JC. Chloroquine inhibition of cholera toxin. FEBS Lett 1990;275:143-5
  • Leppla SH, Dorland RB, Middlebrook JL. Inhibition of diphtheria toxin degradation and cytotoxic action by chloroquine. J Biol Chem 1980;255:2247-50
  • Komiyama T, Swanson JA, Fuller RS. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine. Antimicrob Agents Chemother 2005;49:3875-82
  • Śolaja BA, Opsenica D, Smith KS, et al. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J Med Chem 2008;51:4388-91
  • Eldredge HB, Denittis A, Duhadaway JB, et al. Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. J Radiat Oncol 2013;2:315-21
  • Choi DS, Blanco E, Kim YS, et al. Chloroquine eliminates cancer stem cells through deregulation of JAK2 and DNMT1. Stem Cells 2014;32:2309-23
  • Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013;73:3-7
  • University of Pennsylvania. Combination antineoplastic therapy. US2012129810; 2012
  • Jalan Rajiv. Treatment of liver cancer. US2013315940; 2013
  • University of Pennsylvania. Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use. WO2012149186; 2012
  • University of Basel. Combination of lysosomotropic or autophagy modulating agents and a GSK-3 inhibitor for treatment of cancer. WO2013182519; 2013
  • Medigen Biotechnology Corp and Texas Biogene Inc. Synergistic combination for treating a cancer. WO2013192224; 2013
  • The Texas A&M University System and Scott & White Healthcare. Diagnosis and treatment of cancer using differentially expressed starvation markers. WO2014018801; 2014
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital. Hydroxychloroquine linolenate and synthesis method. CN103772277; 2014
  • Kandula Mahesh. Compositions and methods for the treatment of cancer. WO2014141057; 2014
  • Oosten V, Bernhard A. Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field. EP2561868; 2013
  • University of Colorado. Methods and products for treating proliferative diseases. US2011318335; 2011
  • Guangzhou Kaipu Biological Technology Co. Ltd. Medicament for preventing and treating reproductive organ cancer and application thereof. CN104188969; 2014
  • Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJM. Effect of hydroxychloroquine on progression of dementia in early alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455-60
  • D’Amato RJ, Alexander GM, Schwartzman RJ, et al. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 1987;327:324-6
  • Corfas G, Murtie JC. Treatments for neuropathy. US2011086878; 2011
  • Tokugawa K, Yamamoto K, Nishiguchi M, et al. XIB4035, a novel nonpeptidyl small molecule agonist for GFRα-1. Neurochem Int 2003;42:81-6
  • Department of Veterans Affairs and Stanford Junior University. Desethylhydroxychloroquine for the treatment of diseases associated with inflammation. US2014275164; 2014
  • Guilin Medical University. Application of prednisone and hydroxychloroquine to preparation of compound anti-inflammatory drug. CN103599109; 2014
  • Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007;2(1):e6
  • Burrows JN, Chibale K, Wells TNC. The state of the art in anti-malarial drug discovery and development. Curr Top Med Chem 2011;11:1226-54
  • Egan TJ, Hunter R, Kaschula CH, et al. Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity. J Med Chem 2000;43:283-91
  • Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem 2011;3:1413-26
  • Njoroge M, Njuguna NM, Mutai P, et al. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. Chem Rev 2014;114:11138-63
  • Van Huijsduijnen RH, Guy RK, Chibale K, et al. Anticancer properties of distinct antimalarial drug classes. PLoS One 2013;8:1-11

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.